What doesn’t kill you doesn’t make you stronger

Industry
By
AP Staff
-

References

  1. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med 2021;27(4):601–15. 
  2. Australian Institute of Health and Welfare. Chronic respiratory conditions. 2024. At: www.aihw.gov.au/reports/chronic-respiratory-conditions/chronic-respiratory-conditions/contents/summary
  3. Constantino V, Grafton Q, Kompas T, et al. The public health and economic burden of long COVID in Australia, 2022–2024: a modelling study. Med J Aust 2024;221(4):217–23. 
  4. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Prevention, Diagnosis and Management of COPD: 2023 Report. At: https://goldcopd.org/2023-gold-report-2/ (org)
  5. Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med 2022;28(11):2398–405. 
  6. Australian Institute of Health and Welfare. Older Australians. Canberra: AIHW; 2023. At: aihw.gov.au/reports/older-people/older-australians/contents/summary
  7. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360(9343):1347–60.
  8. Australian Bureau of Statistics. Disability, Ageing and Carers, Australia: Summary of Findings. Canberra: ABS; 2018. At: www.abs.gov.au/statistics/health/disability/disability-ageing-and-carers-australia-summary-findings/latest-release 
  9. Public Health Communications Collaborative. Still Here: Communicating about Long COVID. 2025. At: https://publichealthcollaborative.org/communication-tools/still-here-communicating-about-long-covid/(org)
  10. Terrie YC. The role of the pharmacist in overcoming vaccine hesitancy. US Pharm 2021;45(4):28–31.
  11. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. Geneva: WHO; 2021. At: who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 
  12. Van Beusekom M. RSV vaccine 75% effective against hospitalization in older adults. Minneapolis: CIDRAP; 2024. At: www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/rsv-vaccine-75-effective-against-hospitalization-older-adults-cdc  
  13. Notarte KI, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. eClinicalMedicine 2022;53:101624.
  14. Xie Y, Choi T, Al-Aly Z. Nirmatrelvir and the risk of post-acute sequelae of COVID-19. JAMA Intern Med 2023;183(7):632–40. 
  15. Whimbey E, Ghosh S. Respiratory syncytial virus infections in immunocompromised adults. Curr Clin Top Infect Dis 2000;20:232–55. 
  16. Asthma Australia. A life affected by severe asthma. 2024. At:  https://asthma.org.au/about-asthma/severe-asthma/
  17. Lung Foundation Australia. Overview: chronic obstructive pulmonary disease.2025. At: https://lungfoundation.com.au/patients-carers/living-with-a-lung-disease/copd/overview/